HC Wainwright Reaffirms “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $21.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 162.50% from the company’s current price.

A number of other brokerages also recently commented on ITOS. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research report on Friday, January 10th. Wells Fargo & Company lowered their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a report on Thursday, December 19th.

iTeos Therapeutics Trading Up 3.4 %

Shares of ITOS stock opened at $8.00 on Thursday. iTeos Therapeutics has a twelve month low of $7.09 and a twelve month high of $18.75. The company has a market capitalization of $292.27 million, a price-to-earnings ratio of -2.54 and a beta of 1.39. The firm has a 50-day moving average price of $8.02 and a 200 day moving average price of $11.58.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. As a group, research analysts predict that iTeos Therapeutics will post -3.49 earnings per share for the current year.

Insider Activity at iTeos Therapeutics

In other news, CFO Matthew Gall acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were bought at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the acquisition, the chief financial officer now directly owns 65,429 shares in the company, valued at $505,766.17. This trade represents a 8.27 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.50% of the stock is owned by insiders.

Institutional Trading of iTeos Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Clearline Capital LP purchased a new stake in iTeos Therapeutics during the second quarter worth approximately $2,328,000. Algert Global LLC lifted its holdings in shares of iTeos Therapeutics by 92.0% during the 3rd quarter. Algert Global LLC now owns 256,139 shares of the company’s stock valued at $2,615,000 after acquiring an additional 122,730 shares in the last quarter. State Street Corp boosted its position in iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock worth $12,000,000 after purchasing an additional 211,452 shares during the period. Dimensional Fund Advisors LP boosted its position in iTeos Therapeutics by 14.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after purchasing an additional 117,159 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in iTeos Therapeutics by 3.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company’s stock valued at $2,268,000 after purchasing an additional 8,397 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.